Skip to main content
. 2016 Feb 5;7(11):12672–12681. doi: 10.18632/oncotarget.7208

Figure 1. PFS according to randomisation.

Figure 1

All randomised patients (n = 13) who achieved disease control with neoadjuvant chemotherapy were randomised to arms A (n = 7) and B (n = 6). After a median follow-up of 61.2 months, no differences in median PFS from randomization were observed between arm A [median 7.6 months (95%CI: 5.1 - 10.3)] and arm B [median 9.5 months (95%CI: 4.1 - 15.0)]. RT = radiotherapy, FLUO: Fluoropyrimidine and CETUX = cetuximab.